Skip to main content

Medical staff monitor brain scans of patient Tony Lightfoot during his High Intensity Focused Ultrasound (HIFU) treatment at Sunnybrook Hospital Tuesday Dec. 18, 2012. Doctors at the Hospital for Sick Children in Toronto have removed a benign tumour from a 16-year-old boy Jack Campanile’s leg bone using a cutting-edge heat procedure that does away with any form of invasive surgery. Jack is believed to be the first pediatric patient in North America to be treated using high-intensity focused ultrasound, or HIFU, to destroy the tumour, called an osteoid osteoma.

Tim Fraser/The Globe and Mail

Doctors at the Hospital for Sick Children in Toronto have removed a benign tumour from a 16-year-old boy's leg bone using a cutting-edge heat procedure that does away with any form of invasive surgery.

Jack Campanile of Brampton, Ont., is believed to be the first pediatric patient in North America to be treated using high-intensity focused ultrasound, or HIFU, to destroy the tumour, called an osteoid osteoma.

The procedure uses magnetic resonance imaging to precisely pinpoint the tumour, which is then zapped with heat-destroying ultrasound beams.

Story continues below advertisement

"What's unique about MRI-guided ultrasound is it's completely non-invasive, so there's no incisions," said Dr. James Drake, who leads Sick Kids' Centre for Image Guided Innovation and Therapeutic Intervention.

"We can actually see what's happening to the tissue adjacent to the bone, so we know we're on target, and we can also tell the temperature we're achieving is sufficient to destroy the lesion, but also not damage anything that's nearby."

For almost a year, Jack had been suffering with severe pain in his upper leg, which woke him up in the night and often made it difficult to play some of the sports he loves: hockey, wakeboarding and snowboarding.

"It was like somebody Charlie-horsing me over and over again or somebody having my femur bone over top of their knee and trying to shape it into a hockey blade," he said in an interview Tuesday. "I couldn't sit still and on a scale of one to 10, it was definitely an eight or a nine."

Prior to his July 17 ultrasound procedure, the Grade 11 student said he had been taking three or four ibuprofen tablets a day, and estimated he downed about 700 of the painkillers over the course of the year.

"It was like a painkiller schedule that I didn't ask for."

When he was presented with the idea of being treated with HIFU, he and his dad, Tony Campanile, embraced the idea because it was non-invasive. Jack's mom, Robin Shupe, was initially unsure about the procedure, but said the team of specialists provided all the information she needed to quiet her concerns.

Story continues below advertisement

Treatment for the non-cancerous bone tumour used to involve open surgery to remove the tumour; that gave way to a less invasive treatment that uses radio frequency waves or laser energy delivered through a needle inserted though the skin and into the bone. But that widely used technique carries the risk of side-effects, including infection, burning of surrounding tissue and bone fracture.

HIFU has been employed for some time in Europe to treat osteoid osteoma, but in North America it is mostly used to remove uterine fibroids and malignant tumours.

Dr. Michael Temple, an interventional radiologist who led the team that performed Jack's procedure, believes MRI-guided focused ultrasound represents a key step in the evolution of treatment for osteoid osteoma.

"The fact that we've moved from an open surgical procedure to a minimally invasive procedure to a completely non-invasive procedure is really why I think this treatment is important," Temple said.

"We can now treat these tumours without making an incision. It's actually our hope that we'll be able to advance this technology to use it in different types of both benign and malignant diseases in children."

Waking up at home the day after his procedure, Jack discovered his pain was gone – and it hasn't come back.

Story continues below advertisement

Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter